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ABSTRACT 
Dioxins are widespread environmental pollutants, known to cause immunosuppression, 
developmental and reproductive defects, as well as cancer. The toxic effects of dioxins 
are mediated by the aryl hydrocarbon receptor (AhR, also referred to as the dioxin 
receptor). Dioxins display endocrine disrupting properties and especially disturbances 
of the estrogen signaling system has been reported. Effects of dioxins on the estrogen 
system have been observed at several levels, e.g., increased metabolism of estrogen and 
interactions of the AhR with signaling of the estrogen receptors. As a result of the 
endocrine disrupting properties, dioxins might cause different responses in females and 
males. Bone is a dynamic tissue highly regulated by numerous factors, where estrogen 
is one of the key players. Bone loss is a well known effect of estrogen deficiency and 
can lead to osteoporosis, e.g., in post-menopausal women. A few studies have shown 
that dioxins interfere with bone tissue, however the mechanisms remain unknown. 
Moreover, no studies have been performed regarding potentially gender-related effects 
of dioxins in adult bone tissue. 
Humans are continuously exposed to low levels of dioxins from early embryonic 
development throughout life. Therefore, we studied a transgenic mouse with a 
constitutively active AhR (CA-AhR). The bone phenotype of the female CA-AhR mice 
displayed loss of bone tissue, which was primarily due to an increased bone resorption. 
The bones in females also became softer, which might indicate an altered 
mineralization. The bones of CA-AhR males were on the other hand largely unaffected. 
However, male rats exposed to a single high dose of TCDD displayed alterations in the 
trabecular bone tissue already after five days exposure, indicating a responsiveness of 
bone tissue of either gender towards dioxins. 
Gender-specific responses were also observed in differentiation cultures of osteoclasts 
derived from bone marrow cells of transgenic mice. Consistent with the in vivo results, 
bone marrow cultures from CA-AhR females displayed an elevated osteoclast 
formation. In contrast, osteoclast differentiation was inhibited in cultures from the 
transgenic males. At variance to the CA-AhR females, osteoclast differentiation in 
cultures from female wild type mice exposed to dioxin, did not display an increased 
osteoclast differentiation, which might be due to differences in the mode of AhR 
activation. The CA-AhR represents a chronic exposure situation, mimicking a long 
term, low dose exposure, which the cells might have adapted to, while the TCDD 
exposure is more acute and possible inducing additional effects. Osteoclast 
differentiation in the cultures from the male wild type mice exposed to TCDD 
responded similarly to the osteoclasts derived from CA-AhR, i.e. inhibition of 
osteoclast formation. 
The results in this thesis show that bone is a sensitive target for dioxin exposure, 
leading to rapid alterations in trabecular bone tissue and gene expression in bone cells. 
Moreover, females seem to be more severely affected by a continuously active AhR 
than males. Specifically, the resorption of bone mediated by osteoclasts was altered in a 
gender specific manner by chronic activation of the AhR. Thus, continuous exposure to 
low levels of AhR ligands, such as dioxins and related environmental toxins, might be 
one part of the explanation for the increased incidence of osteoporosis in aging women. 
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INTRODUCTION 
DIOXIN 
Polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans 
(PCDFs) are persistent environmental pollutants and belong to the group of compounds 
more commonly referred to as dioxins. In total there are 210 congeners, 75 dioxins and 
135 furans, but if the dioxin-like polychlorinated biphenyls (PCBs) are included the 
number of congeners increases [1-4]. The dioxins and the dioxin-like PCBs share a 
similar structure shown in Figure 1. However, not all of the congeners are considered to 
be of toxic concern. The congeners considered being of toxic concern and their 
individual toxic equivalency factors (TEF) are listed in Table 1 [3]. 
 
 
Figure 1. Molecular structure of polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated 
dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs). 
Dioxins are known to cause a variety of adverse effects. For example, at high doses 
dioxins cause chloracne, ocular lesions and wasting syndrome, while the more sensitive 
effects include cancer, immunosuppression, reproductive toxicity and endocrine 
disruption. In 1997 the International Agency for Research on Cancer (IARC) concluded 
that TCDD is a human carcinogen [5]. The classification of TCDD as a carcinogen was 
initially controversial, but more recent studies supports the classification of TCDD as a 
human carcinogen (Group 1) [6]. 
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Table 1. Polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) 
and dioxin-like PCBs considered to be of toxic concern, listed together with their respective toxic 
equivalency factor (TEF). The dioxin-like PCBs are listed with their IUPAC number. 
 
 
 
 
          
   Compound TEF    
   Polychlorinated dibenzo-p-dioxins      
  2,3,7,8-TCDD 1   
  1,2,3,7,8-PeCDD 1   
  1,2,3,4,7,8-HxCDD 0.1   
  1,2,3,6,7,8-HxCDD 0.1   
  1,2,3,7,8,9-HxCDD 0.1   
  1,2,3,4,6,7,8-HpCDD 0.01   
   OCDD 0.0003    
   Polychlorinated dibenzofurans      
  2,3,7,8-TCDF 0.1   
  1,2,3,7,8-PeCDF 0.03   
  2,3,4,7,8-PeCDF 0.3   
  1,2,3,4,7,8-HxCDF 0.1   
  1,2,3,6,7,8-HxCDF 0.1   
  1,2,3,7,8,9-HxCDF 0.1   
  2,3,4,6,7,8-HxCDF 0.1   
  1,2,3,4,6,7,8-HpCDF 0.01   
  1,2,3,4,7,8,9-HpCDF 0.01   
   OCDF 0.0003    
   Dioxin-like PCBs      
  PCB 77 0.0001   
  PCB 81 0.0003   
  PCB 126 0.1   
  PCB 169 0.03   
  PCB 105 0.00003   
  PCB 114 0.00003   
  PCB 118 0.00003   
  PCB 123 0.00003   
  PCB 156 0.00003   
  PCB 157 0.00003   
  PCB 167 0.00003   
   PCB 189 0.00003    
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One of the main problems with the dioxins is their resistance to metabolism. The half-
life of TCDD in humans is estimated to ~7.5 years, but varies from 5.1 to 11.3 years [1, 
5]. There are a few congeners with longer half-life (e.g., 1,2,3,7,8-PeCDD) than TCDD, 
however most of the other congeners have a shorter half-life [1]. The half-life is also 
dependent on dose, body composition, age and sex [1, 4]. Dioxins are fat soluble 
compounds that bioaccumulate in organisms, especially in adipose tissue, and are, as a 
consequence of their resistance to degradation and lipophilicity, biomagnified within 
the food-chain. Although dioxins never have been intentionally produced they are 
formed during incineration processes and as byproducts in industrial processes such as 
chlorine bleaching of paper pulp, smelting and manufacturing of herbicides and 
pesticides [7, 8]. This was the case with the well known herbicide called Agent Orange, 
which was extensively used as a defoliant during the Vietnam War. Dioxins are also 
formed naturally in a very small scale during volcano eruptions and forest fires [9]. 
Some incidents with dioxins are reviewed in Box 1. 
 
Humans are primarily exposed to dioxins through food, which contributes with over 
90% of the dioxin exposure. Highest levels of dioxins are found in meat, chicken, egg, 
fish, and dairy products [10]. The risk assessment of dioxins (reviewed in Box 2) 
concluded that the safety margin for dioxin exposure is minimal or non-existing, which 
means that subgroups in the population might be exposed to considerably higher 
concentrations. Moreover, there are risk groups which are more vulnerable to dioxin 
exposure, e.g. fetuses and infants. Moreover, breast fed infants have an intake of 
dioxins that is 1-2 orders of magnitude higher than adults [1, 2]. 
 
Accidental eruptions of dioxins, such as the Seveso accident, have given us some clues 
to the long term effects of dioxin exposure in humans. Nine months after the Seveso 
accident there were considerably more girls being born to parents exposed to TCDD, 
indicating a shift in the sex ratio [11]. Children to dioxin-exposed mothers displayed 
low birth weights, developmental delays, behavioral disorders, hearing loss as well as 
alterations in sexual development [12, 13]. Also certain types of cancer have been 
linked to dioxin exposure, such as multiple myeloma [14]. A 20 years follow-up study 
from the Seveso accident indicate an increased risk of developing cancer in the 
digestive tract (males in the rectum and females in the biliary tract) and in the 
respiratory tract (lung cancer in males) [15]. 
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Box 1 – Incidents with dioxins 
 
2008 – Naples, Italy: Mozzarella cheese, made from buffalo milk, was contaminated with high 
levels of dioxins. 
2007 – India: High levels of dioxins were detected in the food additive called guar gum, a 
thickener in e.g. meat, dairy and desserts. The guar gum was contaminated 
with the pesticide pentachlorophenol (PCF), which contained dioxins [1]. 
2006 – Netherlands: Fat, used in the production of animal feed, was contaminated with dioxins, 
leading to polluted animal feed [1]. 
2004 – Netherlands: High levels of dioxins were detected in milk, which was traced to 
contaminated clay used in the production of animal feed [1]. 
2004 – Ukraine: During the election in 2004 Viktor Yushchenko, president of Ukraine, was 
poisoned with dioxin and his face was disfigured with chloracne [2]. 
1999 – Belgium: High levels of dioxins were discovered in eggs and poultry. Animal feed had 
been contaminated with illegally disposed PCB-based waste industrial oil. 
Subsequently, high dioxin levels were detected in animal based food in 
several other countries [1, 3]. 
1998 – Brazil: Citrus pulp pellets used as animal feed were contaminated with dioxins [1]. 
1997 – USA: Dioxin contaminated bentonite clay, used in the production of animal feed, 
lead to high levels of dioxin in chickens, eggs and catfish [1]. 
1990s – Scandinavia: High levels of dioxin were discovered in fish from the Baltic Sea [4]. High 
dietary consumption of fish from the Baltic Sea was associated with low birth 
weight a Swedish cohort [5]. 
1979 – Taiwan: Rice oil, used in cooking, was contaminated with PCBs, PCDFs and PCDDs, 
resulting in the poisoning of over 2000 people (Yu-Cheng-disease) [6]. 
1976 – Seveso, Italy: An explosion in a chemical factory released more than 30 kg TCDD into the 
environment and contaminated 25 km2 [7]. 
1968 – Japan: In Kyusho, in Japan, a strange skin disease appeared, the Yusho-disease. This 
skin lesion was chloracne caused by PCB and PCDF contaminated rice oil 
used in cooking [6]. 
1960s – Vietnam: US Air Force used the heavily dioxin-contaminated Agent Orange as a 
defoliant during the Vietnam War. It is estimated that 3000 villages and at 
least 2.1 million people were sprayed directly with Agent Orange [8]. 
 
[1] WHO, Dioxins and their effects on human health, Fact sheet N°225, 2007. 
[2] O. Sorg, M. Zennegg, P. Schmid, R. Fedosyuk, R. Valikhnovskyi, O. Gaide, V. Kniazevych, J.H. Saurat, 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: identification and measurement of TCDD metabolites, 
Lancet 374 (2009) 1179-1185. 
[3] R. Guitart, S. Croubels, F. Caloni, M. Sachana, F. Davanzo, V. Vandenbroucke, P. Berny, Animal poisoning in Europe. Part 1: 
Farm livestock and poultry, Vet J  (2009). 
[4] B.G. Svensson, A. Nilsson, M. Hansson, C. Rappe, B. Akesson, S. Skerfving, Exposure to dioxins and dibenzofurans through the 
consumption of fish, The New England journal of medicine 324 (1991) 8-12. 
[5] L. Rylander, U. Stromberg, L. Hagmar, Decreased birthweight among infants born to women with a high dietary intake of fish 
contaminated with persistent organochlorine compounds, Scandinavian journal of work, environment & health 21 (1995) 368-375. 
[6] Y. Aoki, Polychlorinated biphenyls, polychlorinated dibenzo-p-dioxins, and polychlorinated dibenzofurans as endocrine 
disrupters--what we have learned from Yusho disease, Environmental research 86 (2001) 2-11. 
[7] P.A. Bertazzi, I. Bernucci, G. Brambilla, D. Consonni, A.C. Pesatori, The Seveso studies on early and long-term effects of dioxin 
exposure: a review, Environmental health perspectives 106 Suppl 2 (1998) 625-633. 
[8] R. Stone, Epidemiology. Agent Orange's bitter harvest, Science (New York, N.Y 315 (2007) 176-179. 
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The aryl hydrocarbon receptor - AhR 
Dioxins and related aryl hydrocarbons bind to the aryl hydrocarbon receptor (AhR) and 
most, if not all, toxic effects caused by dioxins are mediated by binding and activating 
this receptor [16]. The AhR belongs to the family of basic helix-loop-helix 
(bHLH)/PER-ARNT-SIM homology transcription factors [17]. AhR resides in the 
cytosol together with two molecules of Hsp90, p23 and the immunophilin-like protein 
XAP2 (Figure 2). Upon ligand binding the complex dissociates and the receptor 
undergoes a conformational change that exposes a nuclear localization signal (NLS). 
The ligand-bound AhR is transported into the nucleus where it forms a heterodimer 
with its partner protein AhR nuclear translocator (Arnt, also known as hypoxia 
inducible factor-1β (HIF-1β)). This heterodimer binds to specific regions in DNA 
called xenobiotic responsive elements (XREs or dioxin responsive elements; DREs) 
[17]. Activation of the AhR will result in induction or repression of diverse array of 
genes. The most well studied gene for AhR activation is cytochrome P450 1A1 
(CYP1A1) and the most potent inducer of CYP1A1 is TCDD [18]. CYP1A1 
metabolizes endogenous substrates such as arachidonic acid (AA), bilirubin and 
estrogen [19], but also exogenous compounds such as caffeine, flunarizine (a selective 
calcium-entry blocker) and R-warfarin [20]. 
 
 
Figure 2. Simplified pathway of AhR signaling. The AhR resides in the cytosol with 2 Hsp90, XAP2 and 
p23. Upon ligand binding of the AhR, the complex dissociates, translocates into the nucleus and AhR 
forms a heterodimer with Arnt. The AhR/Arnt-dimer binds XRE in the DNA and modulates the 
transcription of various genes, e.g., induction of CYP1A1 is a widely accepted marker for AhR activity.
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AhR diversity 
AhR is a well conserved protein found in vertebrates and invertebrates. The earliest 
homologs of the receptor are found in metazoans. In vertebrates there are at least three 
members in the AhR gene family, AhR1, AhR2 and AhR repressor (AhRR). Mammals 
however, have only one of the AhRs [21]. Fish have both AhR genes; AhR1 and AhR2. 
AhR 1 is the ortholog to the mammalian AhR, however, AhR 2 is the predominant 
form in fish [21]. An interesting feature of the invertebrate AhRs is their inability to 
bind typical AhR ligands, suggesting that the role in regulating xenobiotic metabolizing 
enzymes evolved in vertebrates [22]. 
 
Although the physiological role of the AhR is not fully established it is suggested to be 
important in the development of different organs, which has been demonstrated in 
studies with mice lacking the AhR (AhR knock out; AhRKO). AhRKO mice display 
alterations in e.g. the liver [23], immune system [24], ovary [25] and heart [26], 
indicating the importance of a functional AhR during the development of certain 
organs. AhR null-mice are resistant to dioxin toxicity, implying the fundamental role of 
AhR in mediating the toxic effects of dioxins [27]. 
 
There is a great variety in the sensitivity towards dioxins, both between species and 
within the same species. Regarding acute toxicity, hamsters are among the most dioxin 
resistant mammals, while the guinea pig is one the most sensitive mammal known [28]. 
The rat strain Long-Evans (L-E) is 1000-fold more sensitive to acute dioxin exposure 
compared to Han/Wistar (H/W) rats. The difference between the L-E rats and the H/W 
rats is due to a point mutation in the resistant H/W strain resulting in an altered splicing 
and lack of approximately 40 amino acids in the trans-activation domain of the AhR 
[29]. Also mice differ in sensitivity to AhR ligands. The C57BL/6 encodes an alanine 
in codon 375 in the ligand binding domain, resulting in a 10 fold higher ligand binding 
affinity for TCDD compared to other mouse strains carrying a valine in this position, 
e.g. the DBA/2 mouse strain [30]. 
 
Endogenous AhR-ligands 
No endogenous high affinity ligand to the AhR receptor has been identified, however 
there are both endogenous compounds and dietary compounds with the ability to bind 
the AhR. Several photooxidation products, generated by UV radiation of the amino 
acid tryptophan, have been shown to bind and activate the AhR with high affinity [31]. 
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FICZ (6-formylindolo[3,2-b]carbazole), a product of UV radiation, was identified as an 
AhR ligand with high affinity for the receptor [32]. Moreover, metabolites of FICZ 
have recently been identified in human urine [33]. Also other potential endogenous 
ligands to the AhR have been suggested, e.g., metabolites of arachidonic acid (AA) and 
tetrapyrrols [31]. 
 
Also dietary ligands to the AhR have been identified, and these include curcumin, 
carotinoids and flavonoids. Although the majority of these ligands are weak agonists, 
some dietary indoles, such as tryptophan, can be converted into more potent AhR-
ligands in the digestive tract [31]. 
 
AhR knock out mouse 
Han/Wistar rats are resistant to dioxin exposure due to a deviant AhR. Similar, mice 
completely lacking an AhR (AhRKO) are also resistant to dioxin exposure. AhRKO 
mice exposed to TCDD do not display the typical toxic effects observed in wild type 
mice exposed to TCDD, such as wasting syndrome, thymic atrophy and teratogenic 
effects [27, 34-36]. However, the AhRKO mice also indicate the requirement for a 
functional AhR in the development of certain organs, such as the liver and immune 
system [23, 24]. Also, reproduction in these mice were reduced, where the female 
AhRKO displayed difficulties maintaining the conceptuses during pregnancy [37]. 
 
The CA-AhR mouse 
In contrast to the knock out of the AhR, a model with a constitutively active AhR (CA-
AhR) has been developed in our laboratory. The mutated constitutively active AhR 
(CA-AhR) was generated by partial deletion of the minimal ligand-binding domain of 
the AhR and does not require ligand for activation (Figure 3) [38]. 
 
Figure 3. Structure of the wild type AhR (upper) and the construct encoding the constitutively 
active AhR (CA-AhR) (lower). 
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Previous studies of this mouse model have concluded that the activity of the mutated 
receptor resembles continuous exposure to low doses of dioxins. Some of the typical 
effects in wild type mice exposed to dioxin are also observed in these transgenic mice, 
e.g. CYP1A1 induction, thymus atrophy and increased liver weights [39, 40]. In 
transgenic mice the hepatic induction of CYP1A1 corresponds to a single dose 
exposure of 0.3 µg TCDD/kg bw in wild type mice [39]. Thus, the activity of CA-AhR 
is relatively low. 
 
These transgenic mice display a reduced life-span, which correlated to the development 
of tumors in the glandular part of the stomach [39]. Interestingly, animals treated with 
AhR ligands have been reported to display similar gastric lesions [41, 42]. Further 
investigation of these gastric tumors revealed that the expression of osteopontin was 
reduced in the CA-AhR mice [43]. Also the immune system was affected in these 
transgenic mice. The CA-AhR mice display an enlarged population of mature bone 
marrow derived B cells [40], which also has been reported in dioxin exposed wild type 
mice [44]. However, the population of peritoneal B1 cells was decreased in CA-AhR 
mice [40]. There seem to be some gender-related alterations in certain organs of the 
CA-AhR mice, where the relative kidney and heart weights were increased in male CA-
AhR mice but not females [45]. Also a suspected tumorigenic effect on liver was 
demonstrated in the male CA-AhR mice [46]. 
 
A similar transgenic mouse has been generated by Nohara et al. [47]. The expression of 
the constitutively active receptor was under the regulation of the T cell specific CD2 
promoter and the CA-AhR was reported to be expressed in thymus, spleen, lung and to 
a minor extent in the kidney. The activity of the CA-AhR in thymus, measured by 
CYP1A1, corresponded to the exposure of a single dose of 20 μg TCDD/kg bw, which 
reflects a considerably higher activity of the CA-AhR compared to our CA-AhR 
mouse. The mice were fertile, displayed normal sex-ratio at birth and no increased 
mortality after birth. However, like the transgenic mice in our laboratory, the thymus 
weight was reduced in female transgenic mice [47]. 
 
TCDD cause chloracne in humans and one postulated mechanism for this effect might 
be an impact of TCDD on keratinocytes [48, 49]. A third transgenic mouse with a 
constitutively active AhR has been generated, where the construct encoding the 
receptor was under the regulation of the human keratin 14 (K 14) promoter and 
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expressed in keratinocytes. These mice develop inflammatory skin lesions and the 
expression of many inflammation-related genes was increased (e.g., IL-1β and IL-18) 
[50]. Increased expression of IL-1β has also been reported in two keratinocyte cell lines 
treated with TCDD [51]. 
 
Non-genomic effects of dioxins 
Although most of the effects are thought to be mediated by the AhR, non-genomic 
effects have also been reported. In male rats TCDD stimulated the activity of 
extracellular signal-regulated kinases (ERKs) [52]. A later in vitro study also showed 
that TCDD and other AhR ligands activated the ERKs and the Jun N-kinases (JNKs) in 
the mitogen-activated protein kinase (MAPK) pathway [53]. After only 10 minutes 
TCDD caused phosphorylation of ERK1/2 and activation of JNKs. Interestingly, 
activation of these kinases did not require the AhR itself, since the activation of the 
kinases was detected in an AhR deficient cell line. Furthermore, activation of the 
MAPKs was crucial for the AhR-dependent transcription of the CYP1A1 gene [53]. 
 
Endocrine disruption 
Dioxins are endocrine disrupting compounds and are well-known to interfere with 
estrogen signaling pathways. Both estrogenic and anti-estrogenic properties have been 
reported. Anti-estrogenic properties of dioxins are well documented and reviewed in 
Safe et al. 2003 [54]. An example is rodent uterus, where dioxin inhibited several 17β-
estradiol (E2) induced responses such as increased uterine wet weight [55], EGF 
receptor binding and EGF receptor mRNA [56] and c-fos mRNA levels [57]. The 
postulated mechanisms for the anti-estrogenic effects of dioxins are: 
 
 Increased metabolism of E2 by CYP1A1 and CYP1B1 [58] 
 Presence of inhibitory DREs (iDRE) in estrogen responsive gene promoters 
(e.g., cathepsin D [59] and c-fos [60]) 
 Competition for common nuclear co-regulatory proteins [61] and  
 Degradation of estrogen receptors [62]. 
 
However, also estrogenic properties of dioxins and AhR-ligands have been reported. In 
estrogen deprived mouse and rat uterus, 3-methylcholantrene (3-MC) and TCDD, 
respectively, induced estrogenic responses [63, 64]. The ligand-activated AhR/Arnt 
complex directly associated with the unliganded estrogen receptor α and β (ERα and 
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ERβ) and induced the transcription of EREs in OVX mouse uterus. However, at high 
doses of estrogen, the AhR-ligands displayed anti-estrogenic properties [63]. 
Furthermore, TCDD induced an estrogen-like response on the gene expression in uterus 
of ovariectomized mice [65]. One hypothesis is that dioxins and dioxin-like compounds 
have different effects in estrogen deprived tissues and in tissues with normal estrogen 
level. For example, the dioxin-like PCB 126 displayed week estrogenic activity in bone 
tissue in estrogen-deprived rats, but when estrogen was present PCB 126 displayed 
anti-estrogenic activity [66]. Also interference with the testosterone signaling pathways 
has been suggested, where anti-androgenic effects were reported [67]. 
 
Health risk assessment 
All dioxins are thought to mediate their toxicity through the same pathway/pathways, 
thus to facilitate the risk assessment the concept of toxic equivalency factors has been 
developed. The toxicity of each congener has been compared to the toxicity of the most 
toxic congener 2,3,7,8-TCDD, which has been given the value of 1. This relative value 
is called toxic equivalency factor (TEF). Individual TEF values together with the 
concentration of each congener can be used to calculate the total toxic equivalence 
(TEQ). The TEQ for each congener can then be added to generate the total TEQ value 
for all congeners in the mixture. 
 
TEQ = (PCDDa x TEFa) + (PCDFb x TEFb) + (PCBc x TEFc) 
 
Several studies have estimated that humans in industrialized countries have a daily 
intake of 1-3 pg TEQs/kg body weight. The risk assessment performed by EU 
concludes that the tolerable daily intake (TDI) is 2 pg TEQ/kg body weight [1, 2]. Thus 
the safety margin for human exposure to dioxins is minimal or non-existing. An 
overview of the risk assessment for dioxin is shown in Box 2. 
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Box 2 – Health risk assessment of dioxins 
 
Risk assessments are based on either a no-observed-adverse-effect-level (NOAEL) or a lowest-
observed-adverse-effect-level (LOAEL), which is extrapolated to a NOAEL using an 
uncertainty factor. Uncertainty factors are also used to extrapolate differences between humans 
and experimental animals and differences in susceptibilities within the human population. 
 
Although data from human exposure were evaluated, the risk assessment of dioxins was based 
on animal studies, where the most sensitive adverse effects following TCDD exposure were 
developmental effects in female and male rats. In the case of dioxins, body burdens were used to 
scale the doses between species, thus no interspecies uncertainty factor was necessary. To 
account for the difference in susceptibility among humans only a small uncertainty factor was 
needed. A total uncertainty factor of 10 for the extrapolation was used to calculate the tolerable 
daily intake (TDI), which ended up at 2 pg TEQ/kg body weight [1, 2]. 
 
The estimated average intake of dioxins for adult humans is 2 pg TEQ/kg body weight/day [3], 
while the intake of breast-fed infants, on a body weight basis, has been estimated to be 1-2 
orders of magnitude greater than for adults [4]. The concentrations of PCDDs, PCDFs and 
dioxin-like PCBs in breast milk have however decreased up to 50% in industrialized countries 
during the last 10 years before the risk assessment was performed. 
 
[1] EC-SCF, Opinion of the Scientific Committee on Food on the risk assessment of dioxins and dioxin-like PCBs in food. 
Adopted on 22 November 2000, SCF/CS/CNTM/DIOXIN/8 final. European Commission Scientific Committee on 
Foods, Brussels, Belgium., 2000. 
[2] EC-SCF, Opinion of the Scientific Committee on Food on the risk assessment of dioxins and dioxin-like PCBs in food. 
Update based on new scientific information available since the adoption of the SCF opinion of 22nd November 2000, 
CS/CNTM/DIOXIN/20 final. European Commission Scientific Committee on Foods, Brussels, Belgium., 2001. 
[3] EC-SCOOP, Assessment of dietary intake of dioxins and related PCBs by the population of EU Member States, 2000. 
[4] A.K. Liem, P. Furst, C. Rappe, Exposure of populations to dioxins and related compounds, Food additives and 
contaminants 17 (2000) 241-259. 
 12 
BONE TISSUE 
Bone tissue is a highly dynamic tissue, which is constantly undergoing catabolic and 
anabolic processes to maintain flexibility and adapt to new demands from the 
environment. It has been estimated that it takes 10 years to completely renew a human 
skeleton [68]. An imbalance either in bone formation or bone resorption can result in 
bone disorders such as osteoporosis and osteopetrosis. 
 
Structurally bone can be divided into two different types: cortical and trabecular bone 
tissue. Cortical bone is a compact structure mainly located at the mid shaft of long 
bones but also comprise the outer shell of bones. Cortical bone has a slow metabolic 
rate and approximately 4% is renewed every year [68, 69]. Trabecular bone tissue is a 
spongy network of trabeculae located inside the cortical shell at the ends of the long 
bones. The metabolic activity of trabecular sites is higher than the metabolic rate in 
cortical bone and roughly 28% is renewed every year. Our skeleton has three main 
functions: to protect vital organs, provide support to our extremities and to act as a 
mineral reservoir for phosphate and calcium [68, 69]. 
 
There are four major cell types in bone tissue: the osteoblasts, the osteocytes, the lining 
cells and the osteoclasts. The osteoblasts produce bone matrix and then become 
encapsulated in the matrix and differentiate further into osteocytes, while the 
osteoclasts resorb bone tissue. During normal conditions, bone formation equals bone 
resorption resulting in a balanced bone remodeling. However, when the balance is 
shifted, in either direction, different pathological conditions can be manifested, such as 
osteoporosis (loss of bone tissue) or osteopetrosis (excess of bone tissue). 
 
Osteoblasts 
The anabolic process of bone formation is performed by the osteoblasts. Osteoblasts 
originate from mesenchymal stem cells (MSC) and a crucial transcription factor for 
osteoblast commitment is Runx2 (also known as Cbfa1). Runx 2 is the earliest 
differentiation marker for osteoblasts currently known and regulates the expression of 
osteoblast genes e.g. type I collagen alpha chain, (Col I) osteopontin (OPN), bone 
sialoprotein (BSP), osteocalcin (OCN) and alkaline phosphatase (ALP) [70, 71]. It is 
now widely accepted that Runx 2 is the master gene of osteoblast differentiation [72]. 
The expression of Runx 2 is regulated by Twist-1, which inhibits Runx 2, and Msx2 
and Bapx1, which both induce Runx 2. Osterix is a Runx 2-dependent transcription 
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factor required for osteoblast differentiation. While Runx 2 also is involved in 
chondrocyte differentiation, Osterix specifically induces osteoblast differentiation [72]. 
The most abundant product from osteoblast activity is collagen type I. About 90% of 
the organic bone matrix is collagen type I, but collagen type V is also present [73]. A 
simplified overview of osteoblast differentiation and fate is shown in Figure 4. The 
bones become hard when the collagen fibrils are deposited with hydroxyapatite 
crystals, a process called mineralization (see “Inorganic bone matrix”) 
 
Osteocytes 
Osteocytes are by far the most abundant cell type in bone tissue and constitute over 
90% of the total number of cells in bone [74]. Osteocytes are further differentiated 
osteoblasts, which have become encapsulated in the mineralized bone matrix. When the 
bone forming process has come to an end the osteoblasts have four options: 
 
 differentiate to osteocytes, 
 transform into lining cells ( see next section) 
 enter apoptosis 
 trans-differentiate into chondrocytes [74]. 
 
The osteocytes are connected to one another via long cell extensions and communicate 
through gap junctions. The life-span of octeocytes varies depending on the remodeling 
rate of the particular bone. If the osteocyte resides in bone with a slow turnover rate, the 
half-life may be decades [75].  
 
The exact role of the osteocytes is still not entirely known, however they are thought to 
function as mechanosensory cells. Their long cell-extensions, connected with gap-
junctions to other osteocytes, lining cells and osteoblasts, enable them to rapidly 
transmit signals. Osteocytes can produce signals that induce or inhibit bone resportion 
as well as factors that inhibit bone formation, e.g. sclerostin [76]. Osteocytes are also 
suggested to have a central role in the mineralization of bone tissue and in the total 
systemic phosphate regulation [77]. 
 
Lining cells 
Like the osteocytes, lining cells are terminally differentiated osteoblasts that cover the 
surface of bone, connected to one another through gap junctions. The exact roles of the 
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lining cells are still not entirely clear. However, they are suggested to prepare the bone 
surface for the osteoclasts by digesting the thin layer of unmineralized osteoid located 
on the bone surface under the lining cells, thereby exposing the bone surface to the 
osteoclasts. The lining cells are also suggested to produce and secrete chemokines that 
recruit osteoclast precursors [78, 79]. 
 
 Figure 4. Overview of osteoblast differentiation from mesenchymal stem cells (MSC) to pre 
osteoblasts (Pre OB) and then into mature osteoblasts (OB). The main products by the mature OB 
are collagen type I, osteopontin, alkaline phosphatase and osteocalcin. 
 
 
 
Osteoclasts 
Bone resorption is performed by multinucleated osteoclasts, which are ultimately 
derived from pluripotent hematopoietic stem cells (HSC). The earliest hematopoietic 
precursor that can form osteoclasts is the CFU-GM, which besides osteoclasts also can 
differentiate into monocytes/macrophages. Macrophage colony stimulating factor (M-
CSF) is an essential cytokine for osteoclastogenesis that stimulates proliferation and 
prevents apoptosis of osteoclast precursors [80, 81]. The most important signal for 
osteoclast differentiation is the interaction of receptor activator of nuclear factor (NF)-
κB ligand (RANKL), produced by osteoblasts in the periosteum and stromal cells in 
bone marrow, with the osteoclast receptor RANK. The crucial roles of RANKL and 
RANK are demonstrated in mice deficient of either RANKL or RANK where 
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osteoclasts are absent. Binding of RANKL to RANK induces the transcription of 
NFATc1, which turns on an autoregulatory loop. Osteoprotegerin (OPG) is a decoy 
receptor for RANKL and can inhibit the RANKL-RANK interaction, thereby inhibiting 
osteoclastogenesis [80-82]. A simplified figure of osteoclast differentiation is shown in 
Figure 5. 
 
 
 
 
 
Figure 5. Simplified picture of osteoclast differentiation from HSC, where the earliest osteoclast 
precursor is CFU-GM. RANKL is the most important factor for osteoclast differentiation and can 
stimulate osteoclast differentiation at several steps 
 
Interestingly, AhR has been suggested to be involved in the regulation of HSC. The 
exact role is not known, but AhR is suggested to regulate the balance between 
quiescence and proliferation in the HSC population [83]. Thus, TCDD might influence 
the precursor population of osteoclasts. 
 
The mature and resorbing osteoclast is highly polarized with specialized membrane 
domains, shown in Figure 6. The process of bone degradation is specifically located to 
the resorption lacunae (RL) and is performed by the ruffled border membrane (RB). To 
demineralize the bone tissue, osteoclasts must retain a low pH value in the resorption 
lacunae, this is performed with a V-type ATPase proton pump and chloride channel 7 
(CCl7) situated in the ruffled border. The organic bone matrix is degraded by lysosomal 
cysteine proteinases, primarily cathepsin K, and matrix metalloproteinases (MMPs), 
such as MMP-9, secreted into the resorption lacunae. Free oxygen radicals may also 
contribute to extracellular matrix degradation [84, 85]. To maintain this acidic and 
rather harsh environment in the resorption lacuna, the membrane of the osteoclast is 
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tightly attached to the bone in the structure called the sealing zone (SZ). One plausible 
mechanism for this is the binding of matrix proteins on the bone surface, such as 
osteopontin, to the integrin αvβ3 on osteoclasts. Also the binding of collagen type I to 
α2β1 and fibronectin to α5β1 are important in the SZ. The waste products, generated in 
the resorption lacunae, are transported in vesicles from the ruffled border to the 
functional secretory domain (FSD), where they are excreted [84, 86]. 
 
 
 Figure 6. During bone resorption the osteoclast is highly polarized with specific membrane domains; 
FSD, functional secretory domain; RB, ruffled border; RL, resorption lacunae and SZ, sealing zone.  
 
 
Bone matrix 
The extracellular bone matrix consists of one organic part and one inorganic part. The 
osteoblasts produce the organic bone matrix, which primarily consists of collagen type 
I, but also collagen type V [87]. The osteoblasts also produce noncollagenous protein 
such as osteopontin (OPN), osteocalcin, fibronectin, osteonectin and alkaline 
phosphatase (ALP) [88]. These proteins are secreted by the osteoblasts and together 
with collagen fibers assemble extracellularly as osteoid matrix. This organic matrix is 
subsequently converted in to hard mineralized bone tissue by deposition of 
hydroxyapatite (Ca5(PO4)3(OH)) crystals on the collagen fibers. Hydroxyapatite is the 
major constituent of bone tissue and contributes to 70% of the total bone mass. The 
noncollagenous proteins, such as osteocalcin and osteopontin are thought to participate 
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in the regulation of the amount and size of the hydroxyapatite crystals. The organic 
matrix contribute to elasticity and flexibility of the bones, while the inorganic matrix 
provides the strength and mechanical rigidity [89]. Structures similar to bone or that 
appears to be bone-like are listed in Box 3. 
 
 
 
 
Box 3. Structures resembling bone 
 
Antlers 
Antlers are the bony appendages carried by many deer species, such as reindeer and moose 
and are the only mammalian bone that is capable of regeneration. In addition, antlers are 
among the fastest growing organs in the animal kingdom, with a maximum growth rate of 4 
cm/day. Antlers consist of bone tissue, although there are differences compared to the bones 
in the skeleton [1]. 
 
Dental tissue 
Similar to bone, dental tissue is also a calcified tissue. The teeth are formed by dentine, which 
largely consists of collagen produced by cells called odontoblasts. These cells share the same 
origin as the osteoblasts and the differentiation is very similar, e.g. Runx 2 controls the 
differentiation of both osteoblasts and odontoblasts[2]. The cells that resorb tooth tissue are 
called odontoclasts and they are almost identical to osteoclasts [3]. Thus dental tissue and 
bone tissue are closely related. 
 
Ivory 
Ivory is used in ornaments and had many practical uses before the plastic era e.g., piano keys 
and Scottish bagpipes. Elephants have been, and still are despite the worldwide ivory trade 
ban in 1989, extensively hunted for their tusks. Also other animals have/had ivory in teeth and 
tusks, e.g. hippopotamus, walrus, mammoth and narwhal. Ivory is formed in the same way as 
dental tissue and therefore resembles bone tissue to a great extent [4]. 
 
Rhino horn 
Rhinos have almost become extinct as a result of hunting. They were hunted because their 
horns were believed to possess medical properties and to functions as an aphrodisiac. Trade 
with rhino horns is illegal since 1993, but poaching occurs. Rhino horn is still used in 
traditional Asian medicine and knife handles in Yemen [5]. Rhino horns consist of 
compressed keratine fibers, lack a bone core and is not attached to the skull. Thus, despite the 
appearance, rhino horn cannot be classified as a bony structure. It is more closely related to 
hair and nails. [6]. 
 
[1] P.Y. Chen, A.Y. Lin, Y.S. Lin, Y. Seki, A.G. Stokes, J. Peyras, E.A. Olevsky, M.A. Meyers, J. McKittrick, Structure 
and mechanical properties of selected biological materials, Journal of the mechanical behavior of biomedical materials 
1 (2008) 208-226. 
[2] S. Camilleri, F. McDonald, Runx2 and dental development, European journal of oral sciences 114 (2006) 361-373. 
[3] J.B. Tyrovola, M.N. Spyropoulos, M. Makou, D. Perrea, Root resorption and the OPG/RANKL/RANK system: a mini 
review, Journal of oral science 50 (2008) 367-376. 
[4] M. Locke, Structure of ivory, Journal of morphology 269 (2008) 423-450. 
[5] J. Still, Use of animal products in traditional Chinese medicine: environmental impact and health hazards, 
Complementary therapies in medicine 11 (2003) 118-122. 
[6] WWF, Världsnaturfonden, http://www.wwf.se/v/arter/1125803-noshorning, 2003. 
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BONE TISSUE AND DIOXINS 
Although bone tissue toxicology is a rather new field of research, a growing number of 
studies suggest that dioxins and other synthetic AhR-ligands disturb bone tissue 
homeostasis. 
 
In vivo 
An in vivo study with two different rat strains, with different sensitivity to dioxins, 
showed the importance of a functional AhR in dioxin mediated bone toxicity [90]. 
Han/Wistar (H/W) rat is less sensitive to dioxin due to a deviant AhR, while the Long-
Evans (L-E) rat with a normal AhR is more susceptible to dioxins [29, 91]. In the 
diaphysis, female L-E rats displayed reduced tibial length decreased bone cross 
sectional size and cortical area at a dose of 1.7 μg TCDD/kg bw. Moreover, the 
mechanical properties of the bones in female L-E rats were altered at 17 μg TCDD/kg 
bw. The breaking force and the stiffness of the bones were reduced, indicating weaker 
and softer bones. Also the trabecular bone tissue was affected, where the trabecular 
bone volume (TBV) was decreased at 17 μg TCDD/kg bw [90]. 
 
However, despite the deviant AhR in the H/W rats, TCDD caused changes in the bones 
of female H/W rats, although at higher doses. Similar responses to the female L-E rats 
were observed in diaphysis of the female H/W rats exposed to 170 μg TCDD/kg bw. 
However, no effect was detected on the TBV [90]. This study clearly demonstrated the 
central role of AhR in TCDD toxicity in bone tissue. The higher doses required to 
induce effects in the female H/W rats are most likely due to the less efficient AhR, 
however, its is intriguing to speculate if non-genomic effects of TCDD can contribute 
to these effects. 
 
In utero and lactational exposure to TCDD caused effects on developing bone tissue in 
a dioxin sensitive rat line [92]. By crossing H/W rats with L-E rats, three different rat 
lines (A, B and C) were generated and they displayed different sensitivity to short-term 
toxic effects of TCDD. Line A was most resistant, line B was less resistant then A, but 
not as sensitive as line C. Three different studies were performed, a dose-response 
study, a timing study and a one-year follow-up study. Bone changes were only seen in 
line C at a maternal dose of 1 μg TCDD/kg bw in the dose response study. Offspring to 
rats exposed to a single dose of 1 μg TCDD/kg bw displayed a reduced cortical bone 
mineral density (BMD) in tibia and reduced cross sectional area (CSA), periosteal 
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circumference, endosteal circumference and cortical BMD in femur [92]. In the timing 
study, both male and female offspring displayed similar changes when the mothers 
were exposed during gestation, postnatally or during lactation. 
 
Female rhesus monkeys exposed to TCDD in utero and through lactation (maternal 
dose of 40.5-42 ng TCDD/kg bw on gestational day 20) displayed increased total bone 
mineral content (BMC), CSA and periosteal circumference in the femoral diaphysis on 
post natal day 90 [93]. However, no alterations were detected in the diaphysis of male 
monkeys. Also the metaphysis was affected by TCDD in female monkeys, where the 
trabecular BMC increased dramatically. No changes were detected in the male 
monkeys. Interestingly, the physical properties of the bones from female monkeys were 
not changed by TCDD, while bones from male monkeys exposed to TCDD (maternal 
dose of 40.5-42 ng TCDD/kg bw) displayed a decreased displacement at failure [93]. 
Thus, although the geometrical dimensions and content in femurs of female monkeys 
were affected this was not reflected in the strength of the bones. The decreased 
displacement in the male monkeys might reflect changes in qualitative parameters that 
cannot be detected by pQCT or three-point bending. It should, however, be noted that 
the TCDD exposed groups in this study were quite small: 6 males and only 3 females 
[93]. 
 
Male mice exposed to TCDD via lactation (maternal dose of 15 μg TCDD/kg bw) 
displayed a reduced amount of mineralized bone in the tibial diaphysis on post natal 
day 21 [94]. Also the metaphysis displayed a reduced amount of mineralized bone, 
while there was an increase in the unmineralized osteoid. The mRNA expression and 
serum levels of bone formation markers were decreased in the TCDD exposed mice, 
suggesting a decreased bone formation. The osteoclast markers were normal, indicating 
normal osteoclast differentiation and resorptive activity. The impaired mineralization 
was explained by reduced osteoblast activity caused by increased level of the active 
form of vitamin D3 [94]. Since osteoclast differentiation markers and osteoclast 
numbers were normal, TCDD might have more pronounced effects on the osteoblasts 
in males. 
 
PCB 126 is one of the most potent dioxin-like PCBs and a study performed with this 
PCB indicates that the endogenous estrogen level is important. PCB 126 and estrogen 
supplementation in ovariectomized rats resulted in increased TBV, while PCB 126 and 
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estrogen decreased the TBV in sham operated animals. The sham operated rats also 
displayed an increased cortical thickness when treated with PCB-126 alone [95]. Thus, 
dioxins might induce different effects in pre-pubertal compared to adult females. 
 
Also other AhR-ligands have shown to interfere with bone tissue homeostasis. Pregnant 
mice were injected with a total dose of 3 mg 3-MC/kg bw and the fetuses were 
examined with whole-mount skeletal and histological examinations. Fetuses to 3-MC 
exposed dams displayed a delayed ossification in the cervical and thoracic vertebrae, 
while the more proximal bones, such as femur and tibia, displayed normal ossification 
[96]. However, it is important to note that 3-MC not is classified as a dioxin-like 
compound and is not only an AhR-ligand. 3-MC also directly binds and activates 
estrogen receptor α (ERα) [97]. 
 
In vitro 
Both osteoblasts and osteoclasts have been shown to express the AhR in vivo, 
suggesting that both cell types are responsive to dioxins [98, 99]. 10 nM TCDD 
inhibited the post-confluent formation of bone nodules in primary osteoblasts from rats 
[100]. In addition, the post-proliferative of activity of ALP and level of osteocalcin was 
inhibited by 10 nM TCDD. Inhibited osteoblast differentiation was also reported after 
exposure to 1 nM TCDD in the chick periosteal osteogenesis (CPO) model, where the 
activity of ALP was reduced by 80% and the mRNA expression by 50% [101]. The 
mRNA expression of BSP, OPN and collagen type I was decreased, as well as the 
protein level of collagen type I. Furthermore, the mineralization was dose-dependently 
reduced in the stromal bone marrow cell (SBMC) model exposed to TCDD [101]. The 
expression of AhR in differentiating osteoblasts from male mice peaked after ALP and 
before the induction of osteocalcin, indicating a role of AhR in normal osteoblast 
differentiation [99]. IGFBP-6 is a potent mitogen of osteoblasts, which was induced by 
TCDD in female rat fetal calvaria and in the human osteosarcoma cell line SaOS-2. The 
authors suggested that the growth inhibitory effects of TCDD on osteogenesis were due 
to the altered IGFBP-6 [102]. Also the expression and secretion of collagenase-3 in 
UMR-106 rat osteosarcoma cells were stimulated by TCDD. The same response was 
also elicited by estrogen, suggesting an estrogenic response of TCDD on osteoblasts 
[103]. 3-MC also inhibited osteoblast differentiation in vitro [96]. 
 
 
   21 
Only two in vitro studies have been performed with osteoclasts exposed to TCDD. The 
activity of primary mature rat osteoclasts was not affected in the presence of TCDD 
[98]. However, differentiation-cultures from male mice displayed an inhibited 
osteoclast formation when exposed to 100 fM TCDD [104]. Also, other AhR-ligands, 
such as 3-MC, have been shown to inhibit osteoclastogenesis [105-107]. 
 
In summary, bone tissue homeostasis in vivo is disturbed by dioxins and this is most 
likely to be mediated by effects on both osteoblasts and osteoclasts. The differentiation 
of osteoblasts and osteoclasts seem to be inhibited by TCDD. However, the activity of 
mature osteoclasts seems to be unaffected. Whether TCDD can influence mature 
osteoblasts or not remains unknown. Also the mechanisms behind the osteoblast and 
osteoclast toxicity are largely unknown. 
 
Gender differences in bone tissue due to AhR ligands 
The study performed with female and male offspring to female rats exposed to 1.0 μg 
TCDD/kg bw during gestation, postnatally and lactation concluded that no gender 
related differences was detected with regard to geometry, densitometry or mechanical 
properties of the bones [92]. In this study the rats were sacrificed at postnatal day 40 
and therefore the investigated rats were not completely sexually mature. Thus, dioxin 
exposure does not seem to cause gender related bone alterations in sexually immature 
rats. 
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PRESENT INVESTIGATION 
AIM OF THE THESIS 
Dioxins are ubiquitously spread environmental pollutants known to cause reproductive 
and developmental defects as well as cancer. During the last decades it has become 
evident that also bone tissue is a target for dioxin exposure. Most effects of dioxins are 
mediated by the AhR, although non-genomic effects have also been observed. 
 
Bone tissue homeostasis is dependent on numerous factors including sex hormones and 
estrogen, in particular, plays an important role. Dioxins display endocrine disrupting 
properties and especially interference of AhR with estrogen signaling pathways has 
been indicated. As a consequence, dioxins or a constitutively active AhR (CA-AhR) 
might influence bone tissue differently in males and females. Moreover, the 
mechanisms for toxicity of dioxins are largely unknown. 
 
Thus, the overall aim of this thesis was to investigate potential gender related effects in 
bone tissue as a result of dioxin toxicity and further elucidate possible mechanisms 
involved. The specific aims for each project are listed below: 
 
¾ The aim of paper I was to investigate the expression and activity of AhR in the 
osteosarcoma cell line UMR-106 after dioxin exposure. A further aim was to 
study the expression of the AhR-responsive and bone-related gene osteopontin 
as possibly involved in effects on bone tissue by dioxins. 
 
¾ The aim of paper II was to investigate if and how acute exposure to dioxin 
affects bone tissue in a short-term perspective. 
 
¾ The aim of paper III was to characterize the bone phenotype of the CA-AhR 
transgenic mice and identify possible differences between male and female 
mice. 
 
¾ Based on the conclusions regarding AhR-regulated bone resorption in paper III, 
the aim of paper IV was to investigate potential effects of an activated AhR 
during osteoclast differentiation. 
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METHODOLOGICAL CONSIDERATIONS 
 
Cell lines (Paper I and IV) 
In paper I and IV two different cell lines were used. In paper I an osteosarcoma cell 
line, UMR-106 (ATCC number: CRL-1661™), from a Sprague-Dawley rat was used to 
study the effects of TCDD on an osteoblast-like cell. The cell line is a clonal derivative 
from the osteosarcoma induced by injection of radiophosphorous. UMR-106 cells 
express receptors for parathyroid hormone (PTH) and 1,25 vitamin D3. The cells also 
display many features of the normal osteoblasts and can mineralize when cultured in 
osteogenic medium. UMR-106 cells also express ALP and osteocalcin [109]. 
 
In paper IV a monocyte/macrophage cell line, RAW 264.7 (ATCC number: TIB-71™), 
from an adult male BALB/c mouse was used to study the effects of TCDD during 
osteoclast differentiation. The cells come from a tumor induced by Abelson murine 
leukemia virus. RAW 264.7 express RANKL and form multinucleated TRAP-positive 
osteoclast-like cells when treated with RANKL [110]. The differentiated cells also 
express the osteoclast markers calcitonin receptor (CTR), cathepsin K and MMP-9 
[111]. 
 
Although these cell lines display many features of osteoblasts and osteoclasts it is 
important to remember that cell lines are immortalized and originate from a cancerous 
tissue. However, they are powerful tools when investigating molecular mechanisms and 
for screening purposes. 
 
CA-AhR mouse model (Paper III-IV) 
The construct encoding the mutant receptor was subcloned into a vector containing a 
strong promoter (SRα), which is a modified viral SV40 promoter and the Eμ enhancer 
of the immunoglobulin heavy chain [112]. This construct also contains a poly 
adenylation site (pA) as well as a splicing region from the SV40 large T gene to 
increase the expression (Figure 3 on page 7). The transgenic mice were created by 
pronuclear injection of C57BL/6 x CBA eggs and then backcrossed into C57BL/6 
resulting in a congenic C57BL/6 background. Therefore C57BL/6N was used as 
control (wild type) animals. The transgenic receptor is expressed in every organ 
examined so far [39, 40]. The transgenic mice also express the endogenous receptor, 
however, this is not activated since no ligand has been administered to the animals. 
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The activity of the CA-AhR, estimated from hepatic CYP1A1 induction, corresponds 
to the CYP1A1 induction in wild type mice exposed to a single dose of 0.3 μg 
TCDD/kg bw, which reflects a rather low activity of the receptor. Furthermore, the CA-
AhR is expressed early in embryo development and throughout life. 
 
Molecular analysis of the human AhR showed that the human AhR shares key 
mutations with the mouse DBA-type AhR and the DBA strain has therefore been 
suggested to be a more suitable model for studying the effects of dioxins [113]. 
However, the genetic background in the CA-AhR mice is C57BL/6, which is a dioxin 
sensitive mouse strain. The C57BL/6 encodes the alanine in codon 375 in the ligand 
binding domain, resulting in a 10 fold higher ligand binding affinity for TCDD, while 
the DBA-type carries valine in this position. However, the binding affinity of human 
AhR for TCDD varies at least 10 fold within the human population [114]. Thus, a 
genetic background of C57BL/6 might be more appropriate when extrapolating to 
humans, especially when considering risk groups and extra sensitive individuals. Taken 
together, these characteristics of the transgenic mouse model make it a relevant model 
for the human exposure situation. 
 
Peripheral quantitative computed tomography – pQCT (Paper II-III) 
Peripheral quantitative computed tomography (pQCT) is a three dimensional X-ray that 
records geometrical and dimensional properties of the intact bone. It is a well 
established technique that can perform separate estimates cortical and trabecular bone 
tissue and measures the true volumetric mineral density [115]. Another frequently used 
method for measuring bone mineral density is dual-energy X-ray (DEXA), however 
DEXA only measures the bone in two dimensions and can therefore only extrapolate 
the volumetric mineral density. pQCT measurement gives a lot of information of which 
parameters that might be altered by a specific treatment, however it cannot determine 
how or if the physical strength of the bones also have changed. Thus, an appropriate 
complement to this method is the three point bending test. 
 
Three point bending test (Paper II-III) 
After the pQCT measurements, the strength of the bones was tested with three point 
bending test. This is the most common method for testing the strength of long bones. 
The strength of the bones is dependent on many factors including mineral content, 
geometrical dimensions of the bones as well as the microarchitecture. The bone was 
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placed on two supports and a load was applied on the mid-diaphyeal area of the bone 
until failure. The three-point bending fixture was connected to a computer that 
registered load (N) and displacement (mm). Based on the load and displacement data it 
is possible to determine load at failure (N), displacement at failure (mm), energy to 
failure (J) and stiffness (N/mm) from the load-deflection curve. The three-point 
bending test reflects the actual strength of the bones, but it cannot determine exactly 
which parameters within the bone that have changed. 
 
Quantitative morphology – stereology (Paper III) 
Stereology is based on the principles of histomorphometry and quantifies three-
dimensional structures from measurements of the structure on two-dimensional 
sections. The method can be used to calculate areas, volumes as well as the numbers 
and areas of specific cell types on sections from the tissue. The quantity of the structure 
is estimated in relative terms, i.e., densities. The density is defined as the quantity per 
volume, area or length within a defined space (tissue volume). 
 
We used a transgenic mouse model to investigate the effects of a constitutively active 
AhR on trabecular bone tissue. The volume densities of trabecular bone and osteoclasts 
were quantified by point counting the micrographs of bone tissue sections using a 
square lattice. Trabecular bone density was calculated as the ratio of the points falling 
on trabecular bone to all the points falling on the tissue volume. 
 
Serum analyses (Paper II-III) 
Bone turnover can be estimated by looking at bone formation markers and bone 
resorption markers in serum. However, a drawback with serum analyses is that the level 
reflects the entire system in an organism. Thus, in most cases it is impossible to 
determine the specific response in a certain organ. However, the C-telopeptide cross-
link of type 1 collagen (CTX) is a specific marker for bone resorption that can be 
measured in serum. CTX is generated by cleavage of the collagen molecule by 
cathepsin K, which is an event specifically performed by the active osteoclasts in bone. 
Thus, CTX measures the resorptive activity of the osteoclasts. While CTX measures 
the activity of the osteoclasts, the serum level of TRAP 5b has in several studies been 
shown to reflect the number of osteoclasts. [116-119]. The ratio of CTX and TRAP 5b 
thereby reflects the resorptive activity normalized to the numbers of osteoclasts and 
may subsequently indicate the individual resorptive activity of each osteoclast. 
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The serum level of the N-terminal propeptide of type I procollagen (PINP) is 
suggested to reflect the bone formation. However, collagen type I is ubiquitously 
expressed and PINP might reflect systemic disturbances in the production of collagen 
type I. 
 
qPCR (Paper I, III and IV) 
Gene expression analysis was performed with quantitative PCR (qPCR), which is a 
very sensitive method that detects small variations in mRNA levels of target genes in 
comparison to reference genes. The sensitivity of the method greatly depends on the 
selection of an appropriate reference gene. It is important that the treatment does not 
affect the gene expression of the reference gene. However, a limitation with this 
method is that the mRNA level of a target gene does not automatically correspond to 
the protein level. Thus is important to analyze especially important genes with other 
additional methods to confirm the results on a functional level, e.g., with Western Blot 
or protein activity assays. 
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RESULTS AND DISCUSSION 
Decreased expression of osteopontin in a rat cell line exposed to dioxin 
Paper I 
Studies with osteoblasts or osteoblast-like cells have suggested that dioxins and other 
AhR-ligands interfere with osteoblast differentiation [96, 99-102, 104, 120], however 
the mechanisms are not fully understood. In Paper I the osteoblast-like cell line UMR-
106 was used to explore potential mechanisms of the toxicity of dioxins on osteoblasts. 
 
Expression of the AhR at the mRNA level had previously been detected in the pre-
osteoblast cell line MCT3T-E1 and in rat calvarial osteoblast-like cells (ROB cells) 
[96]. UMR-106 was found to express the AhR (Figure 1, Paper I), suggesting that 
UMR-106 cells are potentially are responsive to TCDD. Furthermore, the marker gene 
for AhR activity, CYP1A1, was induced (Figure 2, Paper I), confirming that the AhR is 
activated in UMR-106 cells exposed to TCDD. Thus, TCDD is likely to evoke altered 
expression of dioxin-responsive genes in osteoblast-like UMR-106 cells. It was later 
shown that rat osteoblasts express AhR in vivo [99].  
 
In bone tissue, the non-collagenous protein osteopontin (OPN) is produced by the 
osteoblasts in stages just prior to mineralization. OPN binds to the receptor αvβ3, which 
is abundantly expressed on the osteoclasts. The exact role(s) is not yet fully understood, 
but OPN has been suggested to be involved in several processes important for normal 
bone tissue homeostasis, e.g. mineralization, proliferation, migration of bone cells and 
bone resorption [121]. Interestingly, OPN deficiency protected from bone loss observed 
in aging female mice, while no difference was observed in the male mice [122]. 
Moreover, OPN deficient mice are resistant to bone loss caused by ovariectomy [123]. 
In addition, estrogen induces the expression of OPN, further implying hormonal 
influences in OPN function/regulation. 
 
The mRNA expression, estimated by semi-quantitative RT-PCR, of the osteoblast 
differentiation markers, ALP, BSP II, collagen and OPN was decreased in chick 
periosteal osteogenesis (CPO) model exposed to 10 nM TCDD [101]. OPN was also 
identified as a target gene in transgenic mice with a constitutively active AhR, where 
the expression of OPN was reduced in stomach tumors of these mice [43]. UMR-106 
cells also displayed decreased expression of OPN following TCDD exposure (Figure 3, 
Paper I). The decreased expression of OPN was more rapid and sensitive compared to 
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the induction of CYP1A1. The expression level of OPN was decreased after 6 hours at 
1 pM TCDD, while CYP1A1 was induced after 12 hours at 100 pM TCDD. Thus, OPN 
is a more sensitive marker for TCDD exposure in UMR-106 cells than the classical 
TCDD marker gene CYP1A1.  
 
A previous study with UMR-106 cells showed that the secretion of collagenase-3 
displayed a similar response to estrogen and TCDD, suggesting that TCDD has 
estrogenic effects on collagenase-3 secretion [103]. Estrogen has been shown to induce 
the transcription of osteopontin in osteoblasts from mouse [124] and UMR-106 cells 
have been shown to express estrogen receptors [125]. Thus, the decreased expression of 
OPN in paper I suggests an anti-estrogenic effect of TCDD on OPN expression in 
UMR-106. The decreased expression of OPN might result in a decreased capacity of 
the osteoclasts to attach to the bone surface and thereby inhibit bone resorption or favor 
increased mineralization since OPN can act as an inhibitor of mineralization [126]. 
 
Acute exposure to TCDD in vivo affects bone tissue after only five days 
Paper II 
Acute toxic effects of TCDD include chloracne and wasting syndrome. However, bone 
tissue has not previously been studied with regard to short term exposure to dioxins. 
Male Sprague-Dawley rats exposed to a single high dose of TCDD displayed 
alterations in the trabecular part of the bone only five days after of exposure to TCDD. 
The total BMD in the metaphysis was increased, while the trabecular cross sectional 
area (CSA) was decreased (Table 1A, Paper II). No changes were detected in the 
cortical part of the bone (Table 1B and Table 2, Paper II), however changes at the 
cortical site was not expected after 5 days since the remodeling rate of cortical bone is 
slow. 
 
Also serum markers for bone remodeling were altered in response to dioxin exposure. 
The bone formation marker PINP was decreased in TCDD exposed rats (Figure 1A, 
Paper II), suggesting that bone formation is decreased by TCDD. Decreased formation 
of bone might be due to decreased differentiation of osteoblasts, which would fit well 
with the in vitro studies showing that osteoblastogenesis is inhibited by dioxins [96, 99-
102, 104, 120]. However, it is unlikely that effects on differentiation of osteoblasts 
would be detectable after only five days exposure in vivo, especially since the life-span 
of an osteoblast can be 3 month [127]. A more likely explanation would be increased 
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death of osteoblasts by apoptosis. It is also important to remember that PINP is a 
proteolytic fragment from the pro collagen type I molecule and that collagen type I is 
not specific to bone. On the contrary, collagen type I is ubiquitously expressed and a 
decreased PINP level might therefore reflect other systemic disturbances of collagen 
bio-synthesis and turn-over induced by an active AhR. 
 
The bone resorption marker CTX was increased in TCDD exposed rats (Figure 1B, 
Paper II) indicating an elevated activity of the osteoclasts. This can be mediated by 
increased number of osteoclasts or enhanced resorptive activity per osteoclast. An in 
vitro study showed that the activity of mature osteoclasts was not disturbed by TCDD 
[98], indicating that the results in paper II can be explained by an increased 
differentiation of osteoclasts. 
 
The mineral composition of the bones was altered in rats exposed to TCDD. The degree 
of mineralization was not changed but the relative amount of crystalline phosphate was 
increased, while the relative amount of acid phosphate was decreased in the TCDD 
treated rats (Table 3, Paper II). Thus, the mineral composition of bones from TCDD 
resembled the situation in more mature bone tissue. The mineralization process of 
calcified tissues (e.g. bone and teeth) has been suggested to be affected by TCDD in 
other in vitro and in vivo studies (refs), however the mechanisms remain unknown. One 
protein suggested to be involved in mineralization is the osteoblast-produced protein 
osteopontin. Purified bovine osteopontin has been shown to inhibit apatite formation 
and growth [128], bind to hydroxyapatite crystals and modulate bone crystal maturation 
[129, 130]. The expression of osteopontin was decreased as a result of TCDD exposure 
in UMR-106 cells (Paper I). The effects on mineralization in Paper II further support 
the notion that the osteoblasts are affected, either by an inhibited activity of the 
osteoblasts or increased osteoblast cell death. 
 
In summary, the results in Paper II imply a direct or indirect impact on mature 
osteoblasts and an increased differentiation of osteoclasts by TCDD, which is observed 
after only five days exposure. 
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An activated AhR results in gender-specific bone responses 
Papers III and IV 
The importance of a functional AhR in dioxin mediated bone toxicity was 
demonstrated by studying rats with different AhR structures [90]. The rat strain with a 
dysfunctional transactivation domain (Han/Wistar) displayed resistance to dioxin 
exposure, while the bone tissue in rats with a functional AhR (Long-Evans) was 
considerably more affected. Bones from female Long-Evans rats displayed altered 
growth, modeling as well as physical properties when exposed to TCDD. The 
Han/Wistar strain displayed alterations in a few parameters, albeit at much higher doses 
of TCDD [90]. 
 
In paper III and IV a transgenic mouse model with a constitutively active AhR (CA-
AhR) was used to investigate the long term effects of an activated AhR in bone tissue 
and during osteoclast differentiation. In paper III the bone phenotype of female and 
male transgenic mice with a constitutively active AhR (CA-AhR) was investigated, 
where the females were found to be more strongly affected than the males. Based on 
the findings in paper III, an in vitro study of osteoclast differentiation was conducted on 
bone marrow cells from CA-AhR females and males (Paper IV). In Paper IV osteoclast 
differentiation was also assessed in the RAW 264.7 cell line and in bone marrow cells 
from female and male wild type mice exposed to TCDD. The TCDD exposure can be 
viewed as an acute exposure in comparison to the chronic exposure in the CA-AhR 
mice. 
 
Females 
The CA-AhR females displayed changes both at trabecular and cortical parts of tibia. 
The trabecular area and trabecular bone mineral content (BMC) were increased in CA-
AhR females, while the trabecular BMD was unchanged (Table 2, paper III). However, 
an increased trabecular area and content might be recorded even though there is an 
increased resorption. This is because endocortical resorption can lower the volumetric 
cortical BMD at the inner surface so it falls below the threshold value for cortical bone 
and falls into the range for trabecular bone [115]. 
 
The cortical part of the bone displayed slightly wider bones with a decreased density 
(Table 3, paper III). Thus, at the cortical site there seems to be an elevated bone 
resorption, a decreased bone formation or a combination of both. In contrast to the 
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results in paper III, female rats exposed to 1.7 μg TCDD/kg bw displayed smaller 
bones, both with regard to the length and the width of the tibia compared to the control 
animals [90]. The conflicting results might be due to species differences, type of 
exposure or stage of sexual maturation when starting exposure. The transgenic mouse 
model mimics a continuous low dose exposure present during embryo development, 
while the TCDD exposure is more acute and leaving less possibility for adaptive 
responses. The effects in the transgenic mice are the long-term effects, while the effects 
in the TCDD exposed animals reflect early responses. Also the activity of the AhR is 
likely to be different. The activity of the CA-AhR has been estimated to mimic a single 
dose of 0.3 μg TCDD/kg bw, which is almost six fold lower than 1.7 μg TCDD/kg bw. 
Moreover, the CA-AhR has been active since early embryo development, while the 
TCDD exposure started when the rats were 10 weeks and lasted for 20 weeks [90]. 
Another aspect could be that TCDD has been shown to elicit AhR independent non-
genomic responses [53], which not would be possible in the transgenic mouse. Female 
offspring exposed in utero to a single maternal dose of 1.0 μg TCDD/kg bw on 
gestational day 11 or 15 displayed a reduced cortical BMD [92], which is in agreement 
with the findings in Paper III. 
 
Alterations in the cortical part of bones from female CA-AhR mice were also reflected 
in the physical properties of the bones, where the results suggest softer bones (Table 4, 
Paper III). The stiffness of the bones from female rats exposed to TCDD was also 
reduced at a concentration of 17 μg TCDD/kg bw [90]. Thus, the stiffness of the bones 
seems to be affected similarly by a constitutively active AhR and by an acute TCDD 
exposure in female mice. Altered physical properties of the bones can be due to altered 
content, altered dimensions or altered quality of the bone tissue. All three of these 
factors likely contribute to the phenotype observed in female CA-AhR in Paper III. The 
volumetric cortical BMD (content) decreased, the bones became slightly wider 
(dimensions) and softer (quality). Hence, a constitutively active AhR interferes with 
female bone tissue homeostasis in multiple ways. 
 
Analysis of the serum markers CTX and TRAP 5b suggest that the mean osteoclast 
activity was increased in the female CA-AhR mice (Figure 1, Paper III). Thus, the 
increased resorption in the transgenic females is likely to be mediated by an elevated 
osteoclast activity rather than increased number of osteoclasts. Furthermore, the 
osteoclast volume density was increased in the female transgenic mice (Figure 5B, 
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Paper III). Osteoclast size is positively related to osteoclast activity, i.e. larger 
osteoclasts resorb more actively [131-133]. Hence, in the transgenic female mice the 
bone resorption seems to be elevated, resulting in a decreased bone mass. Interestingly, 
the mRNA expression levels of several osteoclast genes involved in the function of 
osteoclasts (e.g. TRAP, cathepsin K and MMP-9) were decreased in female CA-AhR 
(Table 5, Paper III). The expression levels of the early osteoclast differentiation marker 
were, however, normal. Moreover, the RANKL/OPG ratio was increased indicating a 
slightly elevated drive for osteoclast formation. It is possible that increased osteoclast 
differentiation and elevated bone resorption can activate regulatory feed-back 
mechanisms to decrease the activity of the mature osteoclasts in an attempt to 
normalize the resorption. 
 
In vitro osteoclast differentiation in bone marrow cultures from CA-AhR females 
displayed an increased number of osteoclasts (Figure 6A, paper IV). Also the mRNA 
expression of cathepsin K, MMP-9 and CTR genes were increased in the transgenic 
females (Table 4, paper IV). Thus a CA-AhR in female mice seems to increase the 
differentiation of osteoclasts, which also was indicated by the RANKL/OPG ratio in 
Paper III. However, it needs to be established, by differentiation of bone marrow cells 
from female CA-AhR to osteoclasts on bone slices, if the resorptive activity of these 
osteoclasts is increased or not. 
 
A somewhat different pattern was observed in osteoclast differentiation cultures from 
female wild type mice exposed to TCDD, where the number of osteoclasts was 
unchanged (Figure 3A, Paper IV). However, the activity and protein level of TRAP as 
well as the gene expression of cathepsin K, MMP-9 and CTR were decreased in the 
presence of 10 and 1000 pM TCDD, respectively (Figure 4A, B and Table 2, Paper 
IV), indicating decreased osteoclast activity. Thus, in vitro differentiation of female 
osteoclasts with a CA-AhR seems to lead to opposite outcomes compared to osteoclast 
differentiation cultures from wild type females exposed to TCDD. Initially the 
differentiation of osteoclasts might be inhibited by acute exposure by TCDD in 
females, but when the exposure becomes chronic osteoclast differentiation is increased. 
 
The serum level of the bone formation marker PINP was increased, while ALP, another 
bone formation marker, was decreased in bone extracts from female mice (Figure 2, 
Paper III). The mRNA expression levels of collagen type I and other osteoblast 
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markers, e.g. Runx2, was decreased in bones from the female CA-AhR mice (Table 5, 
Paper III), suggesting AhR mediated disturbances on bone formation. Inhibited 
osteoblast differentiation by dioxins has previously been demonstrated [96, 99-102, 
104, 120], although the mechanisms still remain unknown. Runx2 is the master gene 
for osteoblast differentiation and this factor displayed a decreased mRNA expression in 
CA-AhR females. Hence, it is possible that Runx2 is one of the key mediators in 
dioxin-induced inhibition of osteoblast differentiation. 
 
Males 
The bone phenotype of male transgenic mice with a constitutively active AhR 
displayed almost no differences when compare to the wild type males. In total two 
parameters were altered; the trabecular BMD and the TRAP activity (Table 2 and 
Figure 4B, Paper III). However, in vitro differentiation of osteoclasts from male mice 
was remarkably affected by a CA-AhR and TCDD. 
 
Male transgenic mice with a constitutively active AhR displayed an increased 
trabecular BMD, however, this did not alter the physical properties of the bones (Table 
2 and 4, Paper III). A similar response was seen in male rats after five days exposure to 
a single high dose of TCDD (Paper II). Male mice exposed to TCDD via lactation 
(maternal dose of 15 μg TCDD/kg bw), displayed a dramatic increase in unmineralized 
osteoid and a reduced amount of mineralized bone in the metaphysis, suggesting a 
disturbed mineralization process [94]. Thus, acute exposure to TCDD and a 
continuously active AhR seem induce a similar response in the metaphysis of male 
mice, with increased trabecular bone formation. The transgenic male CA-AhR mice did 
not display any alterations in the diaphysis, however male rats exposed to TCDD in 
utero (maternal dose of 1 μg TCDD/kg bw) displayed decreased cross sectional area 
and cortical BMD in the diaphysis of tibia if they were exposed between gestation days 
11-19 [92]. 
 
The second parameter that was changed in male CA-AhR mice was the TRAP activity, 
which was decreased in bone extracts (Figure 4B, paper III). A decreased TRAP 
activity was also observed in the in vitro differentiation of osteoclasts from male CA-
AhR (Figure 8C, Paper IV), where the gene expression of TRAP, RANK, cathepsin K, 
MMP-9 and CTR also was decreased. In contrast to the in vitro observations in Paper 
IV, osteoclast volume density was not different in male CA-AhR mice compared to 
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wild type male mice (Figure 5B, Paper IV). A similar effect was also observed in male 
mice exposed to TCDD through lactation, where the RANKL/OPG ratio and osteoclast 
numbers were normal. This collectively suggests that the inhibitory effect of a CA-AhR 
in vitro is somehow counteracted by yet unknown factors in vivo. 
 
Similar to the in vitro osteoclast differentiation cultures from male CA-AhR mice, 
TCDD exposure of wild type male osteoclast differentiation cultures resulted in an 
inhibited osteoclast formation (Figure 4A, Paper IV). Also the expression levels of 
several osteoclast markers, both for differentiation and function, were decreased (Table 
3, Paper IV). A short-term study of osteoclast activity showed that the activity of 
mature osteoclasts not was altered by TCDD [98]. However a recent study showed that 
100 fM TCDD was sufficient to inhibit the differentiation of osteoclasts from male 
mice [104]. In vitro differentiation of osteoclasts from male mice was also inhibited by 
3-MC [105]. Both a constitutively active AhR and acute TCDD exposure of male 
osteoclast differentiation cultures in vitro seem to cause an inhibited osteoclast 
differentiation. 
 
Females versus males 
A constitutively activated AhR from early development throughout life results in an 
increased bone resorption, possibly mediated by increased osteoclast differentiation and 
osteoclast activity, in female mice, but not in males. Gender-related differences in bone 
tissue have recently been described in Rhesus monkeys exposed to TCDD, where the 
females seem to be more affected than the male monkeys [93]. Also a study with 
pregnant sheep exposed to the non-dioxin-like PCB 153 displayed gender differences in 
the offspring, where the females exposed in utero seemed to be more severely affected 
than the males [108]. Interestingly, two epidemiological studies in Sweden have 
implied a similar response in humans in cohorts of Swedish fishermen and their wives 
from the Swedish east coast (exposed) and west coast (unexposed). The first study 
showed that women, but not the men, on the east coast had a significantly increased 
risk for vertebral fractures [134]. The second study with these cohorts showed that the 
east coast wives, with a higher intake of fatty fish, had an increased fracture incidence 
compared to the east coast wives consuming less fatty fish. No such association was 
detected in the men [135]. 
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The results from Paper III and IV suggest gender-specific responses to a constitutively 
active AhR in bone tissue and in osteoclast differentiation in vitro. This could be 
mediated by cross talk between the AhR pathway and the estrogen signaling system, 
which is well documented [54, 63, 136-139]. One hypothesis is that dioxins act 
estrogen-like when the endogenous estrogen level is low, such as in males and anti-
estrogenic when the endogenous estrogen level is high, such as in females. This 
hypothesis fits well with the results in Paper III and IV. Moreover, local production of 
estrogens in males might also be a part of the explanation. Aromatase (CYP 19) 
converts androgens into estrogens and peripheral aromatization of androgens is the 
major source of estrogen in males. In bone, aromatase is expressed in the osteoblasts 
but not in the osteoclasts [140]. Thus, aromatase activity in the osteoblasts of transgenic 
male mice could perhaps rescue the anti-estrogenic effects of the CA-AhR. 
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CONCLUSIONS 
The overall conclusion of the present thesis is that bone tissue, as well as the individual 
cell types in bone tissue are sensitive targets for dioxin exposure and that females might 
be more responsive to an activation of the AhR compared to males. 
 
In Paper I we showed that UMR-106 cells express the AhR and identified osteopontin 
as a more sensitive marker for dioxin exposure compared to the traditional dioxin 
marker gene CYP1A1. The decrease in ostepontin gene expression was observed 
earlier and at lower concentrations of TCDD than the induction of CYP1A1. A 
decreased osteopontin expression might alter the capacity of the osteoclasts to attach to 
the bone surface, but can also cause disturbances in mineralization. 
 
In Paper II male rats exposed to a high single dose of TCDD displayed alterations in the 
trabecular bone tissue and in the mineral composition after only five days exposure to 
TCDD. Such a rapid response in bone tissue really high-lights the notion that bone is a 
highly dynamic tissue and also very responsive to dioxins. 
 
In Paper III female mice with a constitutively active AhR (CA-AhR) were considerably 
more affected by an activated AhR, which resulted in bone loss correlated to an 
increased bone resorption. These results correlated to the observations in vitro (Paper 
IV), where osteoclastogenesis was elevated in cultures from transgenic females. The 
bone phenotype in male transgenic mice was almost unaffected, but osteoclast 
formation in vitro was inhibited in cultures from male CA-AhR mice. The different 
response in vivo and in vitro might be explained by yet unknown compensatory 
mechanisms present in male mice. Dioxins display endocrine disrupting properties and 
effects on the estrogen signaling system has been well established. In absence of 
estrogen, dioxins seem to have estrogenic properties, while in presence of estrogen, 
dioxins seem to display anti-estrogenic effects. Thus, the most obvious, and perhaps 
most likely reason for the gender specific responses is different endogenous estrogen 
levels in females and males. Increased bone resorption and bone loss is a well known 
feature of estrogen deficiency, thus the activated AhR in females in Paper III might 
cause anti-estrogenic effects. 
 
Similar to the male CA-AhR mice, in vitro osteoclast formation in cultures from male 
wild type mice, was inhibited when exposed to TCDD. However, in contrast to the 
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elevated osteoclast differentiation in female CA-AhR, osteoclast differentiation in cell 
cultures from female wild type mice did not display an increased osteoclast formation 
during TCDD exposure. This might be explained by non-genomic effects of TCDD, 
such as activation of the MAPK pathway, in the TCDD exposed female cultures. 
Another plausible explanation might be the timing and duration of exposure. The CA-
AhR has been active continuously since early embryo development until adulthood, 
while the TCDD exposure was applied for a shorter period of time in adult mice. This 
discrepancy in the females raises the question whether the effects that are observed 
after a temporary dioxin exposure at a specific age really reflects sustained long term 
effects of dioxin. 
 
Taken together, the results in the present thesis suggest that bone tissue homeostasis 
and the differentiation and activity of bone cells are targets for dioxins. Moreover, the 
response to dioxins seems to be gender specific, therefore further research on dioxin 
induced toxicity on bone would likely benefit from separate studies on females and 
males. 
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FUTURE PERSPECTIVES 
Dioxin-induced inhibition on osteoblast differentiation has been established, however 
the mechanisms still remain unknown. We showed that osteopontin (OPN) is an early 
marker for dioxin induced toxicity in osteoblastic cells, however whether this decreased 
expression results in a defective resorption by the osteoclasts remains to be verified. 
Interestingly, the volume and the number of osteoclasts were increased in OPN 
deficient mice, while the resorptive capacity was decreased [122]. 
 
The finding that male rats exposed to a single high dose of TCDD display alterations in 
bone tissue already after five days exposure, really challenges the common idea that 
bone is a rigid tissue. It would be interesting to know the minimum time required to 
induce alterations in bone tissue. Moreover, this study was performed in male rats and 
from study III and IV females seem to be more severely affected, thus it would be 
interesting to assess if the female rats also were more rapidly and/or more severely 
affected after acute exposure than the male rats. 
 
The gender-related differences in Paper III and IV are really fascinating and raise a lot 
of questions. As mentioned before, one hypothesis is that dioxins exert estrogenic 
properties when endogenous estrogen levels are low and anti-estrogenic features when 
endogenous estrogen levels are high. Thus, it would be interesting to study whether this 
bone phenotype also is established in younger females, before sexual maturity when the 
endogenous levels of estrogen are lower than in adults. It would also be interesting to 
investigate if this bone phenotype is sustained in older females and if the males are 
affected at an older age. Another exiting experiment would be to study the effects of 
ovariectomy in the transgenic mice. If the hypothesis is correct, a CA-AhR in 
ovariectomized females would display estrogenic effects when compared to 
ovariectomized wild type mice. 
 
To further analyze the different response in the female osteoclast differentiation 
cultures from CA-AhR mice and from wild type mice exposed to TCDD, an AhR 
inhibitor could be used. One potential mechanism is the non-genomic effects that can 
be induced by TCDD. Pretreatment of cultures from wild type mice with an AhR 
antagonist prior to TCDD exposure would reveal if dioxin elicit non-genomic 
alterations in osteoclasts. If non-genomic effects cause the different responses, the next 
step could be to use specific inhibitors for the different kinases of the MAPK pathway. 
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